BS_HD4EJYE3
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- os_event
- false
- age_years
- 11.079
- sex
- M
- race
- White
- new_clusters
- C6
- umap1_2d
- 3.919618724
- umap2_2d
- 5.490720412
- umap1_3d
- 2.147818153
- umap2_3d
- -0.944061908
- umap3_3d
- -4.018841581
- dataset
- Med-CBTN
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.370
- OXIDATIVE_PHOSPHORYLATION+0.300
- PI3K_AKT_MTOR_SIGNALING+0.300
- DNA_REPAIR+0.270
- HEDGEHOG_SIGNALING+0.260
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.250
- HEME_METABOLISM+0.150
- ADIPOGENESIS+0.130
- SPERMATOGENESIS+0.080
- XENOBIOTIC_METABOLISM+0.060
Top 10 suppressed
- MYC_TARGETS_V2-0.480
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.250
- HYPOXIA-0.230
- BILE_ACID_METABOLISM-0.210
- ANGIOGENESIS-0.190
- IL2_STAT5_SIGNALING-0.190
- TNFA_SIGNALING_VIA_NFKB-0.190
- E2F_TARGETS-0.180
- INTERFERON_ALPHA_RESPONSE-0.180
- MYC_TARGETS_V1-0.170
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-0372 | Med | Medulloblastoma | 0.786 |
| 2 | MDT-AP-2857 | Med | Medulloblastoma | 0.760 |
| 3 | BS_DFWFBYSN | Med | Medulloblastoma | 0.752 |
| 4 | MDT-AP-1183 | Med | Medulloblastoma | 0.739 |
| 5 | MDT-AP-1158 | Med | Medulloblastoma | 0.739 |
| 6 | MDT-AP-0180 | Med | Medulloblastoma | 0.705 |
| 7 | BS_HTEPAKCM | Med | Medulloblastoma | 0.679 |
| 8 | MDT-AP-2017 | Med | Medulloblastoma | 0.661 |
| 9 | MDT-AP-2859 | Med | Medulloblastoma | 0.653 |
| 10 | MDT-AP-1257 | Med | Medulloblastoma | 0.649 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.370 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.300 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.300 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.270 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.260 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.250 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.150 | Temsirolimus | — uncovered |
| ADIPOGENESIS | 0.130 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.080 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.060 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.050 | Inavolisib | — uncovered |
| APOPTOSIS | 0.040 | Idelalisib | — uncovered |
| COMPLEMENT | 0.040 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.030 | Inavolisib | — uncovered |
| PEROXISOME | 0.030 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.030 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.020 | Idelalisib | — uncovered |